Found: 48
Select item for more details and to access through your institution.
Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-26400-x
- By:
- Publication type:
- Article
Pericardial events associated with ibrutinib‐based therapies for chronic lymphocytic leukaemia in two landmark trials.
- Published in:
- British Journal of Haematology, 2024, v. 205, n. 4, p. 1645, doi. 10.1111/bjh.19710
- By:
- Publication type:
- Article
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 399, doi. 10.1111/bjh.16209
- By:
- Publication type:
- Article
Use of PD‐1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 363, doi. 10.1111/bjh.15508
- By:
- Publication type:
- Article
Jumping translocations, a novel finding in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 2, p. 200, doi. 10.1111/bjh.13422
- By:
- Publication type:
- Article
Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real‐world cohort analysis.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 780, doi. 10.1002/ajh.27241
- By:
- Publication type:
- Article
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 56, doi. 10.1002/ajh.26755
- By:
- Publication type:
- Article
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory Model.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
- Published in:
- 2009
- By:
- Publication type:
- journal article
COUNTERPOINT: Does Chemoimmunotherapy Still Have a Role in CLL?
- Published in:
- Oncology (08909091), 2018, v. 32, n. 6, p. 291
- By:
- Publication type:
- Article
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study.
- Published in:
- Cancers, 2023, v. 15, n. 2, p. 507, doi. 10.3390/cancers15020507
- By:
- Publication type:
- Article
Pirtobrutinib in Relapsed or Refractory CLL and SLL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2024, p. 230
- By:
- Publication type:
- Article
Mechanisms of Resistance to BTK Inhibitors in Patients With Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 7, p. 436
- By:
- Publication type:
- Article
Choosing Between Novel Agents and Chemoimmunotherapy in CLL.
- Published in:
- Clinical Advances in Hematology & Oncology, 2020, v. 18, n. 12, p. 780
- By:
- Publication type:
- Article
Incidence and survival of hematological cancers among adults ages ≥75 years.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 7, p. 3425, doi. 10.1002/cam4.1461
- By:
- Publication type:
- Article
The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
- Published in:
- Cancer Medicine, 2017, v. 6, n. 4, p. 778, doi. 10.1002/cam4.996
- By:
- Publication type:
- Article
BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL.
- Published in:
- Therapeutic Advances in Hematology, 2020, v. 11, p. 1, doi. 10.1177/2040620720912990
- By:
- Publication type:
- Article
Determining the relationship of p16<sup>INK4a</sup> and additional molecular markers of aging with clinical frailty in hematologic malignancy.
- Published in:
- Journal of Cancer Survivorship, 2024, v. 18, n. 4, p. 1168, doi. 10.1007/s11764-024-01591-6
- By:
- Publication type:
- Article
Ibrutinib treatment improves T cell number and function in CLL patients.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
- Published in:
- 2021
- By:
- Publication type:
- journal article
ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S378, doi. 10.1016/S2152-2650(21)01863-2
- By:
- Publication type:
- Article
CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S315, doi. 10.1016/S2152-2650(21)01746-8
- By:
- Publication type:
- Article
Poster: ABCL-040: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent Bruton's Tyrosine Kinase Inhibitor in Previously Treated Mantle Cell Lymphoma and Other Non-Hodgkin Lymphomas: Phase 1/2 BRUIN Study Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S241, doi. 10.1016/S2152-2650(21)01513-5
- By:
- Publication type:
- Article
Poster: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S221, doi. 10.1016/S2152-2650(21)01392-6
- By:
- Publication type:
- Article
Oral Abstract: CLL-039: Pirtobrutinib (LOXO-305), a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01273-8
- By:
- Publication type:
- Article
Next Generation Small Molecules in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S114, doi. 10.1016/j.clml.2019.07.439
- By:
- Publication type:
- Article
Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S283, doi. 10.1016/j.clml.2019.07.221
- By:
- Publication type:
- Article
Acalabrutinib with Obinutuzumab in Treatment-Naive (TN) and Relapsed/Refractory (R/R) Patients with Chronic Lymphocytic Leukemia (CLL): 3-Year Follow-Up.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S281, doi. 10.1016/j.clml.2019.07.218
- By:
- Publication type:
- Article
Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S47, doi. 10.1016/j.clml.2016.07.068
- By:
- Publication type:
- Article
Illness representations and psychological outcomes in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Health Psychology, 2022, v. 27, n. 2, p. 553, doi. 10.1111/bjhp.12562
- By:
- Publication type:
- Article
Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 42
- By:
- Publication type:
- Article
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL/SLL: updated results from the phase 1/2 BRUIN study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 33
- By:
- Publication type:
- Article
Targeting BTK in CLL: Beyond Ibrutinib.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 197, doi. 10.1007/s11899-019-00512-0
- By:
- Publication type:
- Article
Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 4, p. 771, doi. 10.1002/hon.3134
- By:
- Publication type:
- Article
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 12, p. 1353, doi. 10.1002/ajh.25638
- By:
- Publication type:
- Article
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 11, p. 967, doi. 10.1002/ajh.24125
- By:
- Publication type:
- Article
Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.
- Published in:
- Cell & Bioscience, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13578-021-00713-2
- By:
- Publication type:
- Article
Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 5, p. 754, doi. 10.1111/j.1365-2141.2009.08007.x
- By:
- Publication type:
- Article
The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
- Published in:
- Experimental Hematology & Oncology, 2024, v. 13, n. 1, p. 1, doi. 10.1186/s40164-024-00483-w
- By:
- Publication type:
- Article
NOD2 activation enhances macrophage Fcγ receptor function and may increase the efficacy of antibody therapy.
- Published in:
- Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2024.1409333
- By:
- Publication type:
- Article
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01386-1
- By:
- Publication type:
- Article
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation.
- Published in:
- Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01302-7
- By:
- Publication type:
- Article
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.
- Published in:
- EJHaem, 2024, v. 5, n. 5, p. 929, doi. 10.1002/jha2.1013
- By:
- Publication type:
- Article
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry.
- Published in:
- Nature Communications, 2020, v. 11, n. 1, p. N.PAG, doi. 10.1038/s41467-020-17997-6
- By:
- Publication type:
- Article
Active Hexose-Correlated Compound Shows Direct and Indirect Effects against Chronic Lymphocytic Leukemia.
- Published in:
- Nutrients, 2023, v. 15, n. 24, p. 5138, doi. 10.3390/nu15245138
- By:
- Publication type:
- Article